Mineralys Therapeutics, Inc. (MLYS): Total Assets
$661.81M
As of 2025-12-31
$667.85M
As of 2026-06-30
+79.5%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $661.81M | +221.4% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $205.90M | -18.2% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $251.64M | +119.9% | 2025-02-12, Balance as of period end |
| 2022-12-31 | $114.44M | n/a | 2024-03-21, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | 2025-12-31 | $661.81M | +221.4% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $668.19M | -10.3% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $670.77M | -2.1% |
| Immunome Inc. (IMNM) | 2025-12-31 | $683.19M | +184.4% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $638.50M | +81.3% |
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $688.13M | +2.8% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $689.80M | +21.3% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $633.16M | -20.7% |
| Viking Therapeutics, Inc. (VKTX) | 2025-12-31 | $715.73M | -21.2% |
Compare MLYS, PTGX, AMRN, IMNM side by side · Screen every company in Pharmaceutical Preparations ↗